Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanFRA:L74 -4.46%55 Debt-to-EBITDA is 0.50 as of Dec. 2025, which is 47% above its 10-year median of 0.34. GuruFocus rates FRA:L74 with a GF Score™ of 55/100. The stock has 3 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 82.46% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for WuXi XDC Cayman's Debt-to-EBITDA or its related term are showing as below:
FRA:L74'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.34 Max: 0.46
Current: 0.29
During the past 6 years, the highest Debt-to-EBITDA Ratio of WuXi XDC Cayman was 0.46. The lowest was 0.01. And the median was 0.34.
FRA:L74's Debt-to-EBITDA is ranked better than 82.46% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.385
vs FRA:L74: 0.29
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
WuXi XDC Cayman Debt-to-EBITDA Related Terms
WuXi XDC Cayman Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:L74 vs TMO, DHR, NTRA: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
WuXi XDC Cayman (FRA:L74) has a Debt-to-EBITDA of 0.50 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on WuXi XDC Cayman. This is 47% above median its historical median of 0.34. Over the past decade, WuXi XDC Cayman's Debt-to-EBITDA has ranged from 0.01 to 0.46. According to the industry distribution chart, WuXi XDC Cayman ranks #20 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 17.5%.
Is WuXi XDC Cayman's Debt-to-EBITDA too high?
WuXi XDC Cayman's current Debt-to-EBITDA of 0.50 is 47% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.46. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.39. WuXi XDC Cayman's value of 0.50 is 79% below this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #20 out of 114 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #20 out of 114 companies for Debt-to-EBITDA. This places WuXi XDC Cayman in the top 18% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.39. WuXi XDC Cayman's value of 0.50 is 79% below this benchmark. Historically, WuXi XDC Cayman's own Debt-to-EBITDA has ranged from 0.01 to 0.46 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 2.39, WuXi XDC Cayman has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.39, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current Debt-to-EBITDA of 0.50 is 79% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on WuXi XDC Cayman. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current Debt-to-EBITDA is 0.50, which is 47% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (FRA:L74) has a current Debt-to-EBITDA of 0.50. The current Debt-to-EBITDA is 0.50, which is 47% above median its 10-year median of 0.34 and 79% below the Medical Diagnostics & Research industry median of 2.39. WuXi XDC Cayman's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For WuXi XDC Cayman (FRA:L74), the current Debt-to-EBITDA is 0.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
55GF Score
Get the complete analysis for FRA:L74
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L74 has been successfully added to your 
